Overview
Prevent the Downward Spiral: Restoring the Gut Microbiota to Reduce Recurrent C. difficile Infection
Avoid the downward spiral of recurrent C. difficile
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Are we waiting too long? It’s time to get off this ride to avoid the downward spiral of recurrent C. difficile. Paul Feuerstadt, MD, Teena Chopra, MD and Kevin Garey, PharmD, discuss the gut microbiota role, management of C. difficile infection in special populations, safety and efficacy of fecal microbiota transplantation, and emerging microbiota restoration therapies.
This activity is intended for ID specialists, hospitalists, internists, physicians, pharmacists and other clinicians who care for patients at risk of serious Clostridioides difficile infection.
CDI recurrence continues to pose significant burdens on patients, clinicians, and the healthcare system. Clinicians require up-to-date knowledge of guideline recommended antimicrobial therapies and emerging therapies for patient who fail antibiotic therapy. This activity will review management of C. difficile infection in three special patient populations and fecal microbiota transplantation for treatment and prevention of recurrent CDI available and emerging therapies for patients who fail antibiotic therapy including fecal microbiota transplantation.
Upon completion of this activity, participants will be able to:
- Evaluate the role of the gut microbiome in relationship to C difficile infection and approaches to restoration for prevention of recurrent infection
- Discuss clinical risk factors that increase a patient’s risk for recurrent and multiply recurrent C. difficile infection
- Review guideline recommendations for the management of first and subsequent recurrences of C. difficile infection
- Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Section 1: Introduction to C. difficile Infection – Teena Chopra MD, MPH
• Epidemiology
• Risk factors
• Pathogenesis
• Diagnosis
• Treatment
• Epidemiology
• Risk factors
• Pathogenesis
• Diagnosis
• Treatment
Section 2: Special Populations with C. difficile Infection: Getting off the CDI Recurrence Escalator – Kevin W. Garey, PharmD, MS
• Stem cell transplant
• Inflammatory bowel disease
• Chronic kidney disease
Section 3: FMT for the Treatment of CDI – Paul Feuerstadt, MD, FACG, AGAF
• Microbiome
• Shifts in the microbiome seen with CDI
• Foundational studies in CDI
• Safety of FMT
• Pharmaceutically produced therapies
Supported by an educational grant from Ferring Pharmaceuticals, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Teena Chopra, MD, MPH
Professor of Medicine, Division of Infectious Diseases
Corporate Medical Director of Infection Prevention and Hospital Epidemiology, and Antibiotic Stewardship
Wayne State University
Detroit Medical Center
Director of Antibiotic Stewardship and Infection Prevention
Vibra Hospital
Detroit, MI
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Kevin W. Garey, PharmD, MS, FASHP
Professor and Chair
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, TX
Professor of Medicine, Division of Infectious Diseases
Corporate Medical Director of Infection Prevention and Hospital Epidemiology, and Antibiotic Stewardship
Wayne State University
Detroit Medical Center
Director of Antibiotic Stewardship and Infection Prevention
Vibra Hospital
Detroit, MI
Paul Feuerstadt, MD, FACG, AGAF
Gastroenterology Center of Connecticut
Assistant Clinical Professor of Medicine
Yale University School of Medicine
Hamden, CT
Kevin W. Garey, PharmD, MS, FASHP
Professor and Chair
Department of Pharmacy Practice and Translational Research
University of Houston College of Pharmacy
Houston, TX
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE/CPE activity.
The following financial relationships have been provided:
Teena Chopra, MD, MPH
Speakers Bureau: Allergan, Cepheid, Melinta Therapeutics, Inc., Merck & Company, Pfizer
Consulting Agreements: Cepheid, Shionogi, Inc.
Data and Safety Monitoring Board Chari (DSMB): Ferring Pharmaceuticals, Inc.
Paul Feuerstadt, MD, FACG, AGAF
Advisory Board: Ferring Pharmaceuticals, Inc., Rebiotix Inc.
Consulting Agreements: Merck and Company, Ferring Pharmaceuticals, Inc., Rebiotix Inc., Roche Diagnostics, Seres Therapeutics
Speakers' Bureau: Merck and Company
Kevin W. Garey, PharmD, MS
Sources of Funding for Research: Paratek Pharmaceuticals, Inc., Summit Pharmaceuticals International, Tetraphase Pharmaceuticals, Inc.
Consulting Agreements: Summit Pharmaceuticals International
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Therapies under investigation for C. difficile
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
CPE credit will be submitted to CPE Monitor on the first day of each month.
Inquiries may be directed to ACHL at (877) 444-8435, ext. 160.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.25 contact hours.
ACPE Universal Activity Number: 0396-0000-20-048-H01-P
Activity Type(s): Application
